Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal down6.150 -0.120 (-1.914%)
Others

06/06/2018 09:53

[I-bank focus]HSBC raises CSPC Pharma (01093) to HK$28.6

[ET Net News Agency, 6 June 2018] HSBC Global Research raised its target price for CSPC
Pharmaceutical Group (01093) to HK$28.6 from HK$24.6, and retained its "buy" rating.
The research house said favorable policies boost CSPC's finished drug business in 1Q
2018. In 2017, three innovative drugs of CSPC, including NBP injection, Jinyouli and
Nuolining, were newly included into the new National Drug Reimbursement List (NDRL).
Following the implementation of the new NDRL, HSBC expects these inclusions to expand from
the current 17 provincial DRLs to nationwide gradually.
Furthermore, the merger of urban and rural basic medical insurance plans and the
implementation of the tiered diagnosis and treatment system may further unleash grass-root
medical demand, expanding CSPC's finished drug business to the rural market.
Thanks to these policies, HSBC expects sales of innovative and generic drugs to reach
HK$6.4bn and HK$6.7bn with CAGRs of 33% and 11% over 2018-20, respectively. The research
house also lifted its 2018-20 net profit estimates by 11%, 12.6% and 13% to HK$3.8bn,
HK$4.8bn and HK$6bn based on improving margins. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.